Výsledky vyhledávání - "Colin B. Erdman"

Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)

Autor: Nicholas P. Tatonetti, Mo Dimbil, Andrea Demakas, Colin B. Erdman, Keith B. Hoffman

Publikováno v: Drug Safety

Background The US Food and Drug Administration (FDA) uses the Adverse Event Reporting System (FAERS) to support post-marketing safety surveillance programs. Currently, almost one million case reports are submitted to FAERS each year, making it a vast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892ac6568635bb4993217161793a7beb
http://europepmc.org/articles/PMC4206770

Zobrazit plný text záznamu

A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes

Autor: Nicholas P. Tatonetti, Mo Dimbil, Keith B. Hoffman, Colin B. Erdman, Andrea Demakas, Robert F. Kyle, Brian M. Overstreet, Dingguo Chen

Publikováno v: Journal of managed carespecialty pharmacy. 21(12)

Given the multiple limitations associated with relatively homogeneous preapproval clinical trials, inadequate data disclosures, slow reaction times from regulatory bodies, and deep-rooted bias against disclosing and publishing negative results, there

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee93309bc571230fd853b3c74c0a3e97
https://pubmed.ncbi.nlm.nih.gov/26679963

Zobrazit plný text záznamu

The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010

Autor: Keith B. Hoffman, Brian M. Overstreet, Nicholas P. Tatonetti, Mo Dimbil, Colin B. Erdman

Publikováno v: Drug Safety

Background The United States Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) consists of adverse event (AE) reports linked to approved drugs. The database is widely used to support post-marketing safety surveillance prog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ca98531469bc5c44e92d3baaec7546
https://pubmed.ncbi.nlm.nih.gov/24643967

Zobrazit plný text záznamu

Post-approval adverse events of new and old anticoagulants

Autor: Mo Dimbil, Colin B. Erdman, Andrea Demakas, Keith B. Hoffman

Publikováno v: BMJ (Clinical research ed.). 348

Anticoagulants are some of the most widely used drugs worldwide. Dabigatran is commonly assumed to be safer than warfarin, but because debate continues on this question,1 we analysed post-marketing safety signals across this drug class. Drug safety a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef4e23e6af36f172ad74e2708010afce
https://pubmed.ncbi.nlm.nih.gov/24603571

Zobrazit plný text záznamu

Erratum to: The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010

Autor: Keith B. Hoffman, Mo Dimbil, Colin B. Erdman, Nicholas P. Tatonetti, Brian M. Overstreet

Publikováno v: Drug Safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a12b80c6f084488056bf0fcd7ac83c3
http://europepmc.org/articles/PMC4643557

Zobrazit plný text záznamu

Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012

Autor: Andrea Demakas, P. Murali Doraiswamy, Keith B. Hoffman, Mo Dimbil, Colin B. Erdman

Publikováno v: BMJ. 347:f4656-f4656

Publications from Roche and a case-control study suggest that there is no evidence, or plausible mechanism of action, to link neuropsychiatric adverse events to Tamiflu (oseltamivir).1 2 Cochrane Collaborators, the BMJ , and others, however, contend

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6820e1fde15757478d8e778b56f101d0
https://doi.org/10.1136/bmj.f4656

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání